Core Viewpoint - Qianjin Pharmaceutical (600479.SH) has received the drug registration certificate for Fumaric Acid Vonoprazan Tablets (20mg, 10mg) from the National Medical Products Administration, indicating a significant regulatory milestone for the company [1] Group 1: Product Information - Fumaric Acid Vonoprazan Tablets are indicated for the treatment of reflux esophagitis and are used in conjunction with appropriate antibiotics to eradicate Helicobacter pylori [1] - The product was developed by Takeda Pharmaceutical Company and was approved for sale in Japan in December 2014 under the brand name "Takecab" [1] - The product received approval for the Chinese market in December 2019 [1] Group 2: Market Potential - According to Morin Pharma data, the total sales of Fumaric Acid Vonoprazan Tablets in the domestic medical and retail market are projected to reach 532 million RMB by the first half of 2025 [1] Group 3: R&D Investment - As of the date of the announcement, Qianjin Pharmaceutical has invested a total of 15.1511 million RMB in the research and development of Fumaric Acid Vonoprazan Tablets [1]

Core Viewpoint - Qianjin Pharmaceutical has received approval from the National Medical Products Administration for the registration of two new drugs, which may enhance its product portfolio and revenue potential [1] Company Summary - Qianjin Pharmaceutical's subsidiary, Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd., has been granted drug registration certificates for fumaric acid vonoprazan tablets (20mg, 10mg) and empagliflozin tablets (10mg, 25mg) [1] - As of the latest report, Qianjin Pharmaceutical has a market capitalization of 4.4 billion yuan [1] Revenue Composition - For the first half of 2025, Qianjin Pharmaceutical's revenue composition is as follows: - Pharmaceutical production accounts for 55.83% - Pharmaceutical wholesale and retail accounts for 41.72% - Other industries account for 6.91% - Traditional Chinese medicine materials and decoction pieces production accounts for 1.64% - Internal offsets account for -6.1% [1]

证券代码：600479 证券简称：千金药业 公告编号：2025-050 株洲千金药业股份有限公司 关于子公司获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，株洲千金药业股份有限公司（以下简称"公司"）下属子公司湖南千 金湘江药业股份有限公司（以下简称"千金湘江药业"）收到国家药品监督管理 局核准签发的富马酸伏诺拉生片（20mg、10mg）与恩格列净片（10mg、25mg） 的《药品注册证书》。现将相关情况公告如下： 一、药品基本信息 （一）富马酸伏诺拉生片 药品名称：富马酸伏诺拉生片 剂型：片剂 规格：20mg(按 C17H16FN3O2S 计)、10mg(按 C17H16FN3O2S 计) 注册分类：化学药品 4 类 药品上市许可持有人：湖南千金湘江药业股份有限公司 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。质量标准、说明书、 标签及生产工艺照所附执行。药品生产企业应当符合药品生产质量管理规范要求 方可生产销售。 （二 ...

Core Viewpoint - Qianjin Pharmaceutical (600479) is set to enhance its profitability and optimize resource allocation through the acquisition of stakes in Qianjin Xiangjiang Pharmaceutical and Qianjin Xieli Pharmaceutical, aiming to implement its "one main, two auxiliary" strategic plan [1][2]. Group 1: Company Performance - As of September 26, 2025, Qianjin Pharmaceutical's stock closed at 10.37 yuan, down 1.52% from the previous week [1]. - The company's total market capitalization is 4.34 billion yuan, ranking 46th out of 67 in the traditional Chinese medicine sector and 3610th out of 5157 in the A-share market [1]. Group 2: Transaction Details - Qianjin Pharmaceutical plans to issue shares and pay cash to acquire 28.92% of Qianjin Xiangjiang Pharmaceutical and 68.00% of Qianjin Xieli Pharmaceutical, with a total transaction value of 623.47 million yuan [1][3]. - The transaction will increase Qianjin Pharmaceutical's stake in Qianjin Xiangjiang Pharmaceutical to 79.92% and achieve 100% ownership of Qianjin Xieli Pharmaceutical [1][3]. Group 3: Regulatory Approval - The transaction has received registration approval from the China Securities Regulatory Commission (CSRC) and has passed the necessary decision-making procedures [2]. - An independent financial advisor report from Guotou Securities confirms that the transaction complies with regulations and fair pricing, with performance commitment agreements signed by the parties involved [2].

Core Viewpoint - Qianjin Pharmaceutical (600479.SH) is planning to acquire minority stakes in its subsidiaries to accelerate resource integration amid pressure on its operating performance [1][4]. Group 1: Acquisition Details - The company intends to acquire 28.92% of Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd. and 68% of Hunan Qianjin Xieli Pharmaceutical Co., Ltd. through a combination of issuing shares and cash payments [1]. - Post-transaction, the company's ownership in Qianjin Xiangjiang Pharmaceutical will increase to 79.92%, and in Qianjin Xieli Pharmaceutical to 100% [1]. - The total valuation for the acquisitions is approximately 623 million yuan, with Qianjin Xiangjiang valued at 1.247 billion yuan and Qianjin Xieli at 387 million yuan [1]. Group 2: Financial Performance of Subsidiaries - Qianjin Xiangjiang is projected to generate revenues of 640 million yuan and 704 million yuan in 2023 and 2024, respectively, with net profits of 105 million yuan and 107 million yuan [3]. - Qianjin Xieli is expected to have revenues of 232 million yuan and 248 million yuan in the same years, with net profits of approximately 39.16 million yuan and 23.84 million yuan [3]. Group 3: Impact on Qianjin Pharmaceutical - The company has faced pressure on its performance, with revenues fluctuating around 3.6 billion yuan from 2020 to 2024 and net profits showing limited growth [4]. - In the first half of 2025, the company reported revenues of 1.818 billion yuan and a net profit of 128 million yuan, reflecting a year-on-year change of -5.52% and +8.5%, respectively [4]. - The acquisition of profitable subsidiaries is expected to improve the company's profitability [4].

Core Viewpoint - Qianjin Pharmaceutical (600479.SH) is planning to acquire minority stakes in its subsidiaries to accelerate resource integration amid pressure on its operating performance [1][4]. Group 1: Acquisition Details - The company intends to acquire 28.92% of Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd. and 68% of Hunan Qianjin Xieli Pharmaceutical Co., Ltd. through a combination of issuing shares and cash payments [1][2]. - Post-transaction, Qianjin Pharmaceutical's ownership in Qianjin Xiangjiang Pharmaceutical will increase to 79.92%, while it will fully own Qianjin Xieli Pharmaceutical [2]. - The valuation of Qianjin Xiangjiang Pharmaceutical's equity is estimated at 1.247 billion yuan, reflecting an increase of 583 million yuan (87.77% increase) from its book value, while Qianjin Xieli Pharmaceutical's equity is valued at 387 million yuan, with a 164 million yuan increase (73.28% increase) [2]. Group 2: Financial Performance - Qianjin Pharmaceutical's revenue has fluctuated around 3.6 billion yuan from 2020 to 2024, with net profits showing minimal growth, recorded at 297 million yuan, 302 million yuan, 304 million yuan, 320 million yuan, and a decline to 231 million yuan in 2024 [4]. - In the first half of 2025, the company reported revenues of 1.818 billion yuan and a net profit of 128 million yuan, marking a year-on-year revenue decline of 5.52% but a profit increase of 8.5% [4]. - The two subsidiaries are profitable, with Qianjin Xiangjiang Pharmaceutical projected to generate revenues of 640 million yuan and 704 million yuan in 2023 and 2024, respectively, and net profits of 105 million yuan and 107 million yuan [3]. Qianjin Xieli Pharmaceutical is expected to achieve revenues of 232 million yuan and 248 million yuan, with net profits of approximately 39 million yuan and 24 million yuan for the same periods [3]. Group 3: Strategic Implications - The acquisitions are part of the company's strategic plan to enhance its core competitiveness and profitability by integrating the pharmaceutical business segments [3][5]. - The subsidiaries are considered crucial components of the company's "one main and two auxiliary" strategy in the traditional Chinese medicine industrial sector, aiming to leverage marketing and operational advantages for better synergy [3].

证券代码：600479 证券简称：千金药业 公告编号：2025-049 株洲千金药业股份有限公司 关于发行股份及支付现金购买资产暨关联交易报告书修订说明的公告 相较公司于2025年8月30日披露的《株洲千金药业股份有限公司发行股份及支付现金购买资产暨关联交 易报告书（草案）（注册稿）》，本次披露的重组报告书对部分内容进行了更新和修订，主要情况如 下： ■ 注：本说明所述词语或简称与报告书"释义"所述词语或简称具有相同含义。 2025年9月23日 特此公告。 株洲千金药业股份有限公司董事会 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 株洲千金药业股份有限公司（以下简称"公司"、"本公司"或"上市公司"）拟通过发行股份及支付现金方 式购买湖南千金湘江药业股份有限公司28.92%的股权及湖南千金协力药业有限公司68.00%的股权（以 下简称"本次交易"）。 公司于2025年8月30日披露了《株洲千金药业股份有限公司发行股份及支付现金购买资产暨关联交易报 告书（草案）（注册稿）》等文件。具体内容详见公司刊登在上海证券交易所网 ...

Core Viewpoint - The company plans to acquire a 28.92% stake in Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd. and a 68.00% stake in Hunan Qianjin Xieli Pharmaceutical Co., Ltd. through a combination of share issuance and cash payment, with a total transaction price of 623 million yuan [1] Group 1 - The share issuance price is set at 8.41 yuan per share, based on the resolution announcement date of the company's 11th Board of Directors' 9th meeting on September 7, 2024 [1] - Following the completion of the transaction, the company's total share capital will increase to 495 million shares [1] - The direct shareholding ratio of the controlling shareholder, Zhuzhou Guotou, will rise to 34.11%, while the actual controller remains the Zhuzhou State-owned Assets Supervision and Administration Commission [1]

国投证券股份有限公司 关于株洲千金药业股份有限公司 发行股份及支付现金购买资产暨关联交易 独立财务顾问报告 独立财务顾问 二〇二五年九月 独立财务顾问声明和承诺 一、独立财务顾问声明 （一）本独立财务顾问报告所依据的文件和材料由本次交易各方提供，提供 方对所提供文件及资料的真实性、准确性和完整性负责，并保证该等信息不存在 虚假记载、误导性陈述或者重大遗漏。本独立财务顾问不承担由此引起的任何风 险责任。 （二）本独立财务顾问报告是在假设本次交易各方当事人均全面和及时履行 本次交易相关协议和声明或承诺的基础上出具。 （三）本独立财务顾问报告不构成对上市公司的任何投资建议或意见，对投 资者根据本独立财务顾问报告作出的任何投资决策可能产生的风险，本独立财务 顾问不承担任何责任。 之 （四）本独立财务顾问未委托或授权其他任何机构和个人提供未在独立财务 顾问报告中列载的信息，以作为本独立财务顾问报告的补充和修改，或者对本独 立财务顾问报告作任何解释或说明。未经独立财务顾问书面同意，任何人不得在 任何时间、为任何目的、以任何形式复制、分发或者摘录独立财务顾问报告或其 任何内容，对于本独立财务顾问报告可能存在的任何歧义，仅独 ...

千金药业 发行股份及支付现金购买资产暨关联交易报告书摘要 证券代码：600479 证券简称：千金药业 上市地点：上海证券交易所 株洲千金药业股份有限公司 发行股份及支付现金购买资产 暨关联交易报告书摘要 | 项目 | 交易对方 | | --- | --- | | 发行股份及 | 株洲市国有资产投资控股集团有限公司、淮安市列邦康泰化工有限公司、黄 | | | 阳、汤振军、汤曜铭、唐闻伯、邓汝腾、叶胜利、刘金玉、周莉华、金亮、 | | 支付现金购 | | | | 钟林波、张新民、彭华军、王洪锋、雷颖、丁四海、刘军明、陈积安、罗斌、 | | 买资产 | | | | 殷文新、吴永强、彭彩霞 | 独立财务顾问 签署日期：二〇二五年九月 千金药业 发行股份及支付现金购买资产暨关联交易报告书摘要 上市公司声明 本公司及全体董事、监事、高级管理人员保证本报告书及其摘要内容的真实、 准确、完整，对报告书的虚假记载、误导性陈述或重大遗漏负相应的法律责任。 本公司控股股东、董事、监事、高级管理人员声明：如本次交易所披露或提 供的信息涉嫌虚假记载、误导性陈述或者重大遗漏，被司法机关立案侦查或者被 中国证监会立案调查的，在形成调查结论 ...